Zealand Pharma

518

DKK

-2.91 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

-2.91%

-28.89%

-27.6%

-32.73%

-39.63%

-29.67%

+476.84%

+119.49%

+551.57%

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Market cap

36.79B DKK

Turnover

30.77M DKK

Revenue

62.69M

EBIT %

-2,029.37 %

P/E

-

Dividend yield-%

-

Financial calendar

27.3

2025

General meeting '25

8.5

2025

Interim report Q1'25

14.8

2025

Interim report Q2'25

ShowingAll content types

Regulatory press release2/20/2025, 12:00 PM

Zealand Pharma convenes its Annual General Meeting 2025

Regulatory press release2/20/2025, 9:08 AM

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Regulatory press release2/20/2025, 6:00 AM

Zealand Pharma Announces Financial Results for the Full Year 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release2/13/2025, 4:00 PM

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Press release1/7/2025, 4:00 PM

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press release1/6/2025, 4:00 PM

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

Video1/3/2025, 4:28 PM by

Michael Friis, Rasmus Køjborg

Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025

I denne uges Aktier i Vælten runder vi 2024 af med at se nærmere på hvordan OMXC25, og nogle af de underliggende aktier i indekset har klaret sig i det forgangne år. Samtidig kigger vi ind i hvordan nogle af de indekstunge aktier måske kan udvikle sig i 2025.

Regulatory press release12/25/2024, 4:40 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Regulatory press release12/25/2024, 4:30 PM

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Regulatory press release12/19/2024, 7:58 PM

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Press release12/10/2024, 2:00 PM

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press release11/13/2024, 5:00 PM

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Regulatory press release11/11/2024, 4:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Regulatory press release11/7/2024, 6:00 AM

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Regulatory press release10/8/2024, 10:45 PM

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Regulatory press release10/8/2024, 6:40 AM

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Regulatory press release9/30/2024, 3:00 PM

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Press release9/13/2024, 3:01 PM

Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th

Regulatory press release9/12/2024, 3:01 PM

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Regulatory press release9/9/2024, 3:01 PM

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.